CP-461

DRUG5 trials

Sponsors

Astellas Pharma Inc

Conditions

Chronic Lymphocytic LeukemiaCrohn's DiseaseMalignant MelanomaProstate CancerRenal Cell Carcinoma

Phase 1

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

CompletedNCT00036257

Astellas Pharma IncChronic Lymphocytic Leukemia

Start: 2002-03-31End: 2003-04-30Target: 15Updated: 2011-10-17

Phase 2

Study Using CP-461 to Treat Advanced Prostate Cancer

CompletedNCT00036075

Astellas Pharma IncProstate Cancer

Start: 2001-08-31End: 2005-12-31Target: 25Updated: 2011-10-17

Study of CP-461 in Patients With Advanced Renal Cell Cancer

CompletedNCT00036036

Astellas Pharma IncRenal Cell Carcinoma

Start: 2001-07-31End: 2003-07-31Target: 14Updated: 2011-10-17

CP-461 for the Treatment of Crohn's Disease

CompletedNCT00042055

Astellas Pharma IncCrohn's Disease

Start: 2002-07-31End: 2003-09-30Target: 30Updated: 2011-10-17

CP-461 in the Treatment of Patients With Advanced Melanoma

TerminatedNCT00060710

Astellas Pharma IncMalignant Melanoma

Start: 2003-01-31End: 2004-12-31Target: 35Updated: 2011-10-17